Healthcare provider profile · identity verified

Jack N Yu, MD

Family Practice · GLENDALE, CA · NPI 1265485684

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	208	45
Atorvastatin Calcium	Atorvastatin Calcium	196	41
Mirtazapine	Mirtazapine	127	21
Levothyroxine Sodium	Levothyroxine Sodium	107	18
Eliquis	Apixaban	100	12
Furosemide	Furosemide	92	16
Metoprolol Succinate	Metoprolol Succinate	92	19
Tamsulosin Hcl	Tamsulosin Hcl	90	21
Gabapentin	Gabapentin	86	12
Famotidine	Famotidine	80	18
Alendronate Sodium	Alendronate Sodium	78	16
Metformin Hcl	Metformin Hcl	69	17
Losartan Potassium	Losartan Potassium	61	16
Sertraline Hcl	Sertraline Hcl	61	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	56	11
Quetiapine Fumarate	Quetiapine Fumarate	56	11
Trazodone Hcl	Trazodone Hcl	53	13
Clopidogrel	Clopidogrel Bisulfate	49	11
Carvedilol	Carvedilol	48	suppressed
Finasteride	Finasteride	47	suppressed
Celecoxib	Celecoxib	45	15
Simvastatin	Simvastatin	45	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	44	suppressed
Omeprazole	Omeprazole	42	suppressed
Methimazole	Methimazole	41	suppressed
Linzess	Linaclotide	37	suppressed
Lisinopril	Lisinopril	34	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	33	suppressed
Sucralfate	Sucralfate	32	suppressed
Potassium Chloride	Potassium Chloride	31	suppressed
Acarbose	Acarbose	30	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	27	suppressed
Irbesartan	Irbesartan	26	suppressed
Levetiracetam	Levetiracetam	24	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	24	suppressed
Amiodarone Hcl	Amiodarone Hcl	22	suppressed
Aripiprazole	Aripiprazole	22	suppressed
Duloxetine Hcl	Duloxetine Hcl	22	suppressed
Spironolactone	Spironolactone	22	suppressed
Divalproex Sodium	Divalproex Sodium	21	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Hydralazine Hcl	Hydralazine Hcl	21	suppressed
Januvia	Sitagliptin Phosphate	21	suppressed
Pregabalin	Pregabalin	21	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	20	suppressed
Santyl	Collagenase Clostridium Hist.	19	suppressed
Albuterol Sulfate	Albuterol Sulfate	18	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	18	suppressed
Ozempic	Semaglutide	18	suppressed
Tramadol Hcl	Tramadol Hcl	18	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	17	suppressed
Lactulose	Lactulose	17	suppressed
Oxycodone Hcl	Oxycodone Hcl	17	suppressed
Risedronate Sodium	Risedronate Sodium	17	suppressed
Allopurinol	Allopurinol	16	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	16	suppressed
Diltiazem Hcl	Diltiazem Hcl	15	suppressed
Lidocaine	Lidocaine	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Budesonide	Budesonide	14	suppressed
Humalog	Insulin Lispro	14	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Alprazolam	Alprazolam	13	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	13	13
Belsomra	Suvorexant	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Atropine Sulfate	Atropine Sulfate	12	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	12	suppressed
Olanzapine Odt	Olanzapine	12	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	12	12
Timolol Maleate	Timolol Maleate	12	suppressed
Valsartan	Valsartan	12	suppressed
Acetazolamide	Acetazolamide	11	suppressed
Atenolol	Atenolol	11	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	11	suppressed
Cephalexin	Cephalexin	11	suppressed
Eszopiclone	Eszopiclone	11	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	11	suppressed
Morphine Sulfate Er	Morphine Sulfate	11	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error